HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
Stocks · News reference
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.